MSD

We aspire to be the premier research-intensive biopharmaceutical company.

[MSD @MSDInvents]

Today, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME).

Learn more: https://t.co/HAHJ0UO2k5

[MSD @MSDInvents]

Today at #EADVCongress, we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: https://t.co/q3j2q15qww

[MSD @MSDInvents]

@sairyabhb Hi - thank you for reaching out. We’d like to hear more from you. Please contact our Designated Point of Contact in India at [email protected].

[MSD @MSDInvents]

@deepsurya Hi Deepak - thank you for reaching out. We're sorry to hear your frustration. Please contact our National Service Center at [email protected] or [phone] and they can do their best to answer your question.

[MSD @MSDInvents]

Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: https://t.co/1XFsfUGgy5

[MSD @MSDInvents]

Our Q2 2026 #earnings results are live: https://t.co/hhm1tR8OsL

Swipe below for perspective from Chairman and CEO Rob Davis.

[MSD @MSDInvents]

Today we announced our initial post-approval access plans for our investigational HIV prevention option. We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can be accessed by those who need it in low- and middle-income countries.

Learn more: https://t.co/uLB084e4BG

[MSD @MSDInvents]

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: https://t.co/9pDyBXaAqT

[MSD @MSDInvents]

Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: https://t.co/7EzLFGZsUb

[MSD @MSDInvents]

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: https://t.co/m1vFnSYnlS

[MSD @MSDInvents]

Our Q1 2026 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/1FMpZfaBzx

[MSD @MSDInvents]

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation.

This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients.

Learn more about the landmark partnership: https://t.co/2Z4N1yYFbT

[MSD @MSDInvents]

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: https://t.co/mRFXAI5awI #ophthalmology

[MSD @MSDInvents]

We’re sharing Phase 3 results of our investigational oral macrocyclic peptide. Learn more: https://t.co/uCiIT4qzAR

[MSD @MSDInvents]

Today, we announced an agreement to acquire Terns Pharmaceuticals, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: https://t.co/WlX50ZK8bC

[MSD @MSDInvents]

@RastogiSonsy @Merck Hi, it looks like your post may have intended to tag another company. Please note our company is Merck in the US and Canada and @MSDInvents elsewhere.

[MSD @MSDInvents]

Join us today at 9 a.m. ET to learn more about our Q4 and full-year 2025 #earnings: https://t.co/F9TimXkqHU

[MSD @MSDInvents]

Our Q4 and full-year 2025 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/3K1YIbjr2J

[MSD @MSDInvents]

Today, we announced the completion of the acquisition of Cidara Therapeutics, diversifying our pipeline with a novel late-phase antiviral candidate being evaluated for the prevention of symptomatic influenza in certain individuals at high risk of complications. Learn More. https://t.co/JWRKoFIjSG